Company Resources

Introductory Company Profile

SeromYx

Poster from WVIC SF 2019

SeromYx

Company News

SeromYx Systems to present at World Vaccine & Immunotherapy 30- Nov – 2 Dec 2021, Loews Coronado Bay Resort, San Diego. Dr. Todd Suscovich, SeromYx’s Chief Technical Officer will be presenting on how data from Systems Serology studies guided the development of mAb therapies for CoV2.

World Vaccine & Immunotherapy
Nov 30 – Dec 2, 2021

SeromYx Systems participates at the Immuno-Oncology Summit, Westin Copley Place, Boston. Kaustuv Banerjee, Director, Scientific Development will be talking to participants with the objective of understanding how Systems Serology could benefit Oncology programs.

Immuno-Oncology Summit
Oct 4-5, 2021

Founder Galit Alter featured as one of the Boston Globe’s 2020 Bostonians of the Year

Boston Globe Dec 13 2020

SeromYx is on the Scientist.com platform

Case Studies

Correlates Analysis

Identify the mechanistic immune markers associated with natural infection (disease outcome), vaccination, or treatment. 

Therapeutic Antibodies

Downstream of correlates, Systems Serology supports screening therapeutic monoclonal antibodies for desired function. 

Vaccines

Downstream of correlates, Systems Serology supports the development of vaccine design strategies (e.g., prime/boost, dose and timing (e.g., delayed fractional dose), adjuvants)

Assay Development, Qualification, Validation

Which assays need to be demonstrated to be statistically robust so that data from them can be included in regulatory filings? 

Lead Selection

What product construct best delivers the desired mix of function?

Manufacturing Scale-Up

Currently run to a GCLP-like standard, SeromYx expects to be GCLP in 2021.